20 RS BR 1613

A CONCURRENT RESOLUTION establishing the Kentucky Pediatric
 Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections
 (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) Task Force.

WHEREAS, pediatric acute-onset neuropsychiatric syndrome (PANS) is a condition possibly caused by abnormal autoimmune or inflammatory response in the brain following any one of various infections in the body, psychological trauma and underlying autoimmune, neurological, endocrine, or metabolic disorders, or other unidentified non-infectious triggers; and

9 WHEREAS, pediatric autoimmune neuropsychiatric disorders associated with 10 streptococcal infections (PANDAS) is a condition that is a subset of PANS that occurs 11 when the associated infection is known to be a strep infection; and

WHEREAS, PANDAS and PANS create the sudden onset of obsessive-compulsive
disorder in children, causing previously healthy and emotionally adjusted children to
experience severe anxiety and emotional disturbances; and

WHEREAS, children with PANDAS and PANS tend to manifest some of the following symptoms: tics or other abnormal movements, severe separation anxiety, generalized anxiety, irritability, aggression, personality changes, Attention Deficit Hyperactivity Disorder, marked deterioration in learning and school performance, and developmental regression, including regression in handwriting; and

WHEREAS, the National Institute of Mental Health estimates that one in 200 children have PANDAS and PANS, meaning these diseases affect roughly 5,000 children in Kentucky; and

WHEREAS, the number of patients with PANDAS is a small portion of those affected by the family of PANS, but those with PANDAS have a disproportionately high economic, clinical, and social burden for patients, their caregivers, families, employers, and the health care system: and

27

WHEREAS, children with PANDAS and PANS may experience moderate to

dramatic improvement with antibiotics, intravenous immunoglobulin treatment, or
 plasmapheresis; and

WHEREAS, identifying the barriers to PANDAS and PANS awareness, testing,
diagnosis, and early linkage to medication and care would be in the state's best interest;
and

6 WHEREAS, many general pediatricians, nurse practitioners, and pediatric 7 subspecialists are not familiar with the most current diagnostic criteria and treatment 8 guidelines for these disorders; and

9 WHEREAS, in addition to lack of access to treating providers, many insurers do not 10 cover treatment for PANDAS and PANS, which can cost many tens of thousands of 11 dollars, placing it out of reach for most families; and

WHEREAS, researchers are currently engaged in extensive research and testing onhow to effectively treat PANDAS and PANS; and

WHEREAS, it is in the best interest of the Commonwealth that there be greater public awareness of this serious health issue among parents, medical providers, and policy makers, and it is therefore imperative to undertake a study of the needs, issues, and problems associated with this disorder;

18 NOW, THEREFORE,

Be it resolved by the House of Representatives of the General Assembly of the Commonwealth of Kentucky, the Senate concurring therein:

Section 1. The Legislative Research Commission shall establish the Kentucky
 Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal
 Infections (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
 Task Force to provide recommendations to the Cabinet for Health and Family Services,
 health care providers, and the General Assembly on improving research, diagnoses,
 treatments, and education related to PANDAS and PANS.

27

 \rightarrow Section 2. The duties of the task force shall include but are not limited to:

20 RS BR 1613

(1) Studying the benefits of improved awareness of PANDAS and PANS among
 parents, educators, and health care providers and early diagnosis of PANDAS and PANS
 among health care providers;

4 (2) Examining comprehensive medical and behavioral health services for those 5 suffering from this serious autoimmune disorder that have been demonstrated to have a 6 positive impact on medical outcomes and reduced burdens on patients, families, 7 providers, and society; and

8 (3) Identifying barriers to health benefit insurance coverage for care for children
9 with PANDAS and PANS and their families.

Section 3. The task force shall be composed of the following members with the
 final membership of the task force being subject to the consideration and approval of the
 Legislative Research Commission:

13 (1) Two members of the Senate appointed by the President of the Senate, one of
14 whom shall be designated as co-chair of the task force;

15 (2) One member of the Senate appointed by the Minority Floor Leader of the16 Senate.

17 (3) Two members of the House of Representatives appointed by the Speaker of
18 the House of Representatives, one of whom shall be appointed by the Speaker of the
19 House of Representatives as co-chair of the task force;

20 (4) One member of the House of Representatives appointed by the Minority Floor
21 Leader of the House of Representatives;

(5) The secretary of the Cabinet for Health and Family Services or his or herdesignee;

- 24 (6) The commissioner of the Department for Insurance or his or her designee;
- 25 (7) The commissioner of the Department of Education or his or her designee;

26 (8) One licensed psychiatrist to be selected from a list of three names provided by
27 the Kentucky Medical Association;

Page 3 of 4

1 (9) One licensed pediatrician to be selected from a list of three names provided by 2 the Kentucky Medical Association; 3 (10) One public health practitioner to be selected from a list of three names 4 provided by the Kentucky Public Health Association; 5 (11) One licensed health care provider to be selected from a list of three names 6 provided by the Kentucky Hospital Association; 7 (12) One licensed nurse to be selected from a list of three names provided by the 8 Kentucky Nurses Association; 9 (13) One licensed pharmacist to be selected from a list of three names provided by 10 the Kentucky Pharmacists Association; and 11 (14) Two parents of children who have been diagnosed with PANDAS and PANS 12 to be selected from a list of three names provided by the Kentucky Medical Association. 13 \rightarrow Section 4. The task force shall meet monthly during the 2020 Interim of the 14 General Assembly. The task force shall submit findings and recommendations to the 15 Legislative Research Commission for referral to the appropriate committee or committees 16 by December 1, 2020. 17 \rightarrow Section 5. Provisions of this Resolution to the contrary notwithstanding, the 18 Legislative Research Commission shall have the authority to alternatively assign the 19 issues identified herein to an interim joint committee or subcommittee thereof, and to

20 designate a study completion date.

Page 4 of 4